Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: In their Clinical Review, Dr Hankey and colleagues1 discussed medical management for peripheral arterial disease (PAD), which they document as a strong risk factor for cardiovascular morbidity and mortality. While I agree with their advice that all patients with this condition warrant treatment with an antiplatelet drug, I disagree with their statement that aspirin is “the preferred antiplatelet drug because it is effective and inexpensive.”
Hackam DG. Medical Management of Peripheral Arterial Disease. JAMA. 2006;296(1):41-42. doi:10.1001/jama.296.1.41-a